Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
71.2 lbs on average) Retatrutide 9mg: 26.4% body weight reduction Tirzepatide/Zepbound (Phase 3 comparison, not head-to-head): ~20.9% Semaglutide/Wegovy (Phase 3 comparison, not head-to-head): ~14.9% Placebo: ~2.1% Note: These figures come from separate Phase 3 trials and are not direct head-to-head comparisons
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, also demonstrated significant efficacy in a phase II trial for MASH [6]
N Engl J Med 345(12):861869 Moorhead JF, Brunton C, Varghese Z (1997) Glomerular atherosclerosis
The MHRA has not approved any transdermal GLP-1 formulations, and all available GLP-1 therapy is administered via subcutaneous injection
